Details for Patent: 10,959,996
✉ Email this page to a colleague
Which drugs does patent 10,959,996 protect, and when does it expire?
Patent 10,959,996 protects AUSTEDO XR and AUSTEDO and is included in two NDAs.
Protection for AUSTEDO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-four patent family members in twenty-four countries.
Summary for Patent: 10,959,996
| Title: | Methods for the treatment of abnormal involuntary movement disorders |
| Abstract: | Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions. |
| Inventor(s): | Stamler; David (Menlo Park, CA), Huang; Michael Fangching (Ladera Ranch, CA) |
| Assignee: | AUSPEX PHARMACEUTICALS, INC. (North Wales, PA) |
| Application Number: | 16/040,012 |
|
Patent Claim Types: see list of patent claims | Use; |
Recent additions to Drugs Protected by US Patent 10,959,996
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | Feb 17, 2023 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-3055 | A METHOD OF TREATING HUNTINGTON'S CHOREA | |||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | Jul 1, 2024 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-3055 | A METHOD OF TREATING HUNTINGTON'S CHOREA | |||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE | 216354 | May 29, 2024 | RX | Yes | ⤷ Sign Up | ⤷ Sign Up | U-3055 | A METHOD OF TREATING HUNTINGTON'S CHOREA | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 10,959,996
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-001 | Feb 17, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-002 | Feb 17, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Teva | AUSTEDO XR | deutetrabenazine | TABLET, EXTENDED RELEASE;ORAL | 216354-008 | Jul 1, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,959,996
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 103876 | ⤷ Sign Up | |||
| Australia | 2016229949 | ⤷ Sign Up | |||
| Australia | 2021204740 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
